# Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

> **NCT02159573** · — · COMPLETED · sponsor: **Biogen** · enrollment: 530 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** natalizumab
- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT02159573
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2016-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02159573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02159573, "Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02159573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*